Blood Cancer
Johnson & Johnson Looks To Blood Cancer Drug Successor With Early-Stage Deal
Johnson & Johnson team up once more with Genmab to carry a potential successor to Darzalex known as HexaBody-CD38. The ...FDA declines to approve Daiichi Sankyo’s blood most cancers remedy
Japan’s Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib ...‘Living drug’ gives desire to terminal blood cancer patients
NHS patients with lymphoma have for the primary time been given a pioneering treatment that genetically reprogrammes their immune machine ...